Biopsy for liver cancer: How to balance research needs with evidence‐based clinical practice
Boris Blechacz, Lopa Mishra – 11 February 2015
Making sorafenib irresistible: In vivo screening for mechanisms of therapy resistance in hepatocellular carcinoma hits on Mapk14
Matias Avila, Carmen Berasain – 11 February 2015
Reply
Farhan Haq, Sung‐Min Ahn – 11 February 2015
Fibrates and cholestasis
Nisanne S. Ghonem, David N. Assis, James L. Boyer – 11 February 2015 – Cholestasis, including primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), results from an impairment or disruption of bile production and causes intracellular retention of toxic bile constituents, including bile salts. If left untreated, cholestasis leads to liver fibrosis and cirrhosis, which eventually results in liver failure and the need for liver transplantation.
Fibrates and cholestasis
Nisanne S. Ghonem, David N. Assis, James L. Boyer – 11 February 2015 – Cholestasis, including primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC), results from an impairment or disruption of bile production and causes intracellular retention of toxic bile constituents, including bile salts. If left untreated, cholestasis leads to liver fibrosis and cirrhosis, which eventually results in liver failure and the need for liver transplantation.
The origins of hepatobiliary and gastrointestinal physiology
James L. Boyer – 11 February 2015
A molecular mechanism for lipophagy regulation in the liver
Didac Carmona‐Gutierrez, Andreas Zimmermann, Frank Madeo – 11 February 2015
Cost‐effectiveness of hepatitis C treatment for patients in early stages of liver disease
Andrew J. Leidner, Harrell W. Chesson, Fujie Xu, John W. Ward, Philip R. Spradling, Scott D. Holmberg – 11 February 2015 – New treatments for hepatitis C virus (HCV) may be highly effective but are associated with substantial costs that may compel clinicians and patients to consider delaying treatment. This study investigated the cost‐effectiveness of these treatments with a focus on patients in early stages of liver disease.
The role of hepatic resection in the treatment of hepatocellular cancer
Sasan Roayaie, Ghalib Jibara, Parissa Tabrizian, Joong‐Won Park, Jijin Yang, Lunan Yan, Myron Schwartz, Guohong Han, Francesco Izzo, Mishan Chen, Jean‐Frédéric Blanc, Philip Johnson, Masatoshi Kudo, Lewis R. Roberts, Morris Sherman – 11 February 2015 – Current guidelines recommend surgical resection as the primary treatment for a single hepatocellular cancer (HCC) with Child's A cirrhosis, normal serum bilirubin, and no clinically significant portal hypertension. We determined how frequently guidelines were followed and whether straying from them impacted survival.
Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)
Jean‐Claude Trinchet, Valérie Bourcier, Cendrine Chaffaut, Mohand Ait Ahmed, Setty Allam, Patrick Marcellin, Dominique Guyader, Stanislas Pol, Dominique Larrey, Victor De Lédinghen, Denis Ouzan, Fabien Zoulim, Dominique Roulot, Albert Tran, Jean‐Pierre Bronowicki, Jean‐Pierre Zarski, Odile Goria, Paul Calès, Jean‐Marie Péron, Laurent Alric, Marc Bourlière, Philippe Mathurin, Jean‐Frédéric Blanc, Armand Abergel, Lawrence Serfaty, Ariane Mallat, Jean‐Didier Grangé, Catherine Buffet, Yannick Bacq, Claire Wartelle, Thông Dao, Yves Benhamou, Christophe Pilette, Christine Silvain, Christos Christ